← Search & browse all drugs
VARIOUS › DIAGNOSTIC RADIOPHARMACEUTICALS › TUMOUR DETECTION › Technetium (99mTc) compounds
technetium (99mTc) antimelanoma antibody
V09IA02
Forms & Strengths
- Lyophilized kit containing antimelanoma monoclonal antibody, reconstituted with 99mTc pertechnetate
- Single‑use vials, 5‑10 mCi (185‑370 MBq) per vial
- Radiopharmaceutical ready for IV injection
Adult Dosing
- 10‑20 mCi (370‑740 MBq) IV bolus; imaging 2‑4 h post‑injection
- Maximum cumulative activity per year ≤ 100 mCi
Pediatric Dosing
- 0.2‑0.3 mCi/kg IV (max 10 mCi)
- Adjust activity for body surface area in infants
Indications
- Localization and staging of malignant melanoma
- Detection of metastatic melanoma lesions
- Sentinel lymph node mapping in melanoma
Mechanism of Action
- Antibody binds melanoma‑associated antigen (e.g., gp100/MART‑1)
- Tc‑99m emits 140 keV gamma photons for planar/SPECT imaging
- Targeted accumulation highlights melanoma tissue
Contraindications
- Known hypersensitivity to the antibody or kit excipients
- Pregnancy unless diagnostic benefit outweighs fetal radiation risk
- Breastfeeding (discontinue nursing for 24 h)
- Severe renal impairment may delay clearance
Adverse Reactions
- Mild injection‑site pain or erythema
- Transient flushing or headache
- Allergic reactions: urticaria, pruritus, rare anaphylaxis
- Radiation exposure‑related risk: stochastic effects with cumulative dosing
Drug Interactions
- Concurrent administration of other radiopharmaceuticals may cause image interference
- High‑dose IV iron or chelators can reduce Tc‑99m labeling efficiency
- Co‑administered therapeutic antibodies may compete for antigen binding
Curated Content: Needs Vetting Before Put to Clinical Use